ValuEngine Lowers Stryker (SYK) to Hold

ValuEngine lowered shares of Stryker (NYSE:SYK) from a buy rating to a hold rating in a report released on Friday morning.

Several other equities analysts also recently weighed in on the stock. Royal Bank Of Canada reiterated a buy rating and issued a $155.00 price target on shares of Stryker in a report on Friday, September 1st. Argus restated a buy rating and issued a $160.00 price objective on shares of Stryker in a research report on Tuesday, August 29th. Zacks Investment Research lowered Stryker from a hold rating to a sell rating in a research report on Monday, October 16th. Robert W. Baird upgraded Stryker from a neutral rating to an outperform rating and upped their price objective for the stock from $161.00 to $173.00 in a research report on Thursday, November 16th. Finally, Stifel Nicolaus upped their price objective on Stryker from $158.00 to $168.00 and gave the stock a buy rating in a research report on Friday, October 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $152.10.

Stryker (NYSE:SYK) traded down $0.13 on Friday, hitting $155.87. 1,263,800 shares of the stock traded hands, compared to its average volume of 1,181,647. Stryker has a 12-month low of $111.22 and a 12-month high of $160.62. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $58,332.41, a P/E ratio of 24.70, a P/E/G ratio of 2.45 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter in the prior year, the company posted $1.39 earnings per share. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. research analysts expect that Stryker will post 6.47 EPS for the current fiscal year.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in Stryker during the first quarter worth approximately $948,000. Gotham Asset Management LLC acquired a new position in Stryker during the first quarter worth approximately $7,514,000. Investment Centers of America Inc. increased its position in Stryker by 21.2% during the first quarter. Investment Centers of America Inc. now owns 5,409 shares of the medical technology company’s stock worth $711,000 after buying an additional 945 shares during the period. AQR Capital Management LLC increased its position in Stryker by 7.4% during the first quarter. AQR Capital Management LLC now owns 452,895 shares of the medical technology company’s stock worth $59,624,000 after buying an additional 31,159 shares during the period. Finally, Paloma Partners Management Co increased its position in Stryker by 217.2% during the first quarter. Paloma Partners Management Co now owns 6,026 shares of the medical technology company’s stock worth $794,000 after buying an additional 4,126 shares during the period. 74.97% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “ValuEngine Lowers Stryker (SYK) to Hold” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/04/valuengine-lowers-stryker-syk-to-hold.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Stryker (NYSE:SYK)

What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit